CY1115477T1 - Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου - Google Patents

Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου

Info

Publication number
CY1115477T1
CY1115477T1 CY20131100709T CY131100709T CY1115477T1 CY 1115477 T1 CY1115477 T1 CY 1115477T1 CY 20131100709 T CY20131100709 T CY 20131100709T CY 131100709 T CY131100709 T CY 131100709T CY 1115477 T1 CY1115477 T1 CY 1115477T1
Authority
CY
Cyprus
Prior art keywords
compositions
methods
cancer
cancer treatment
treatment
Prior art date
Application number
CY20131100709T
Other languages
Greek (el)
English (en)
Inventor
Alan H Auerbach
Arie S Belldegrun
Original Assignee
Janssen Oncology, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115477(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Oncology, Inc. filed Critical Janssen Oncology, Inc.
Publication of CY1115477T1 publication Critical patent/CY1115477T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20131100709T 2006-08-25 2013-08-20 Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου CY1115477T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25
EP07837326.3A EP2061561B1 (en) 2006-08-25 2007-08-23 Compositions for treating cancer

Publications (1)

Publication Number Publication Date
CY1115477T1 true CY1115477T1 (el) 2017-01-04

Family

ID=38916904

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20131100709T CY1115477T1 (el) 2006-08-25 2013-08-20 Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CY20211100513T CY1124221T1 (el) 2006-08-25 2021-06-10 Συνθεσεις για τη θεραπεια του καρκινου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100513T CY1124221T1 (el) 2006-08-25 2021-06-10 Συνθεσεις για τη θεραπεια του καρκινου

Country Status (20)

Country Link
EP (3) EP3804730A1 (https=)
JP (10) JP2010501575A (https=)
KR (4) KR20200125776A (https=)
CN (2) CN104306977A (https=)
AU (6) AU2007287098C1 (https=)
CA (1) CA2661422C (https=)
CY (2) CY1115477T1 (https=)
DK (2) DK2061561T3 (https=)
ES (2) ES2869343T3 (https=)
HR (2) HRP20130961T1 (https=)
HU (1) HUE054495T2 (https=)
IL (3) IL197211A0 (https=)
LT (1) LT2478907T (https=)
NO (2) NO20091190L (https=)
NZ (1) NZ597830A (https=)
PL (2) PL2061561T3 (https=)
PT (2) PT2478907T (https=)
RS (2) RS62034B1 (https=)
SI (2) SI2478907T1 (https=)
WO (1) WO2008024484A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3804730A1 (en) * 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2009009132A1 (en) * 2007-07-12 2009-01-15 Cougar Biotechnology, Inc. Use of 17alpha-hydroxylase/c17, 20-lyase inhibitors for the treatment of cancer
AR069079A1 (es) * 2007-10-29 2009-12-30 Takeda Pharmaceutical Farmaco para la prevencion o el tratamiento de cancer
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
JP6100700B2 (ja) 2011-01-11 2017-03-22 ノバルティス アーゲー 組合せ
KR102021157B1 (ko) 2011-04-01 2019-09-11 제넨테크, 인크. Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
RU2014154009A (ru) * 2012-06-06 2016-08-10 Новартис Аг Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания
SG11201501870RA (en) 2012-09-26 2015-04-29 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
SG10201907684PA (en) * 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
MX2015013247A (es) * 2013-03-15 2016-11-25 Iceutica Inc Formulacion de acetato de abiraterona.
BR112015025408A8 (pt) * 2013-04-04 2018-07-10 Exelixis Inc combinações de drogas para tratar câncer
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
ES3063787T3 (en) * 2013-10-01 2026-04-20 Novartis Ag Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
JP6355724B2 (ja) * 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
ES2863500T3 (es) * 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
WO2018191141A1 (en) * 2017-04-13 2018-10-18 Janssen Pharmaceutica Nv Combination therapy for prostate cancer
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
JP7644713B2 (ja) * 2019-03-06 2025-03-12 プロペラ セラピューティクス インコーポレイテッド アビラテロンプロドラッグ
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
IL297338A (en) * 2020-04-16 2022-12-01 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2265624B (en) 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
EP1276482B1 (en) * 2000-03-02 2008-01-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
AU2003274823A1 (en) * 2002-10-23 2004-05-13 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
JP2006515623A (ja) * 2003-01-13 2006-06-01 セダーズ−シナイ メディカル センター 化学療法剤としてのパリカルシトール
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
EP3804730A1 (en) 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions for treating cancer

Also Published As

Publication number Publication date
EP3804730A1 (en) 2021-04-14
JP6445123B2 (ja) 2018-12-26
KR20090059126A (ko) 2009-06-10
LT2478907T (lt) 2021-06-25
PT2061561E (pt) 2013-10-09
WO2008024484A1 (en) 2008-02-28
PL2478907T3 (pl) 2021-10-25
EP2061561A1 (en) 2009-05-27
JP2019059750A (ja) 2019-04-18
JP6740497B2 (ja) 2020-08-12
CY1124221T1 (el) 2022-05-27
CA2661422C (en) 2017-06-27
HUE054495T2 (hu) 2021-09-28
AU2017201764A1 (en) 2017-04-06
JP2012082215A (ja) 2012-04-26
NO20091190L (no) 2009-03-20
HRP20130961T1 (hr) 2013-11-22
NZ597830A (en) 2013-02-22
NO20200775A1 (no) 2009-03-20
SI2061561T1 (sl) 2013-11-29
HK1131577A1 (en) 2010-01-29
DK2061561T3 (da) 2013-10-07
RS52956B (sr) 2014-02-28
AU2022206696A1 (en) 2022-08-11
ES2428634T3 (es) 2013-11-08
RS62034B1 (sr) 2021-07-30
JP2017052791A (ja) 2017-03-16
CN101528308A (zh) 2009-09-09
EP2478907A3 (en) 2012-08-01
JP2018065859A (ja) 2018-04-26
IL257681A (en) 2018-04-30
AU2007287098C1 (en) 2018-03-15
AU2015221447A1 (en) 2015-09-17
PL2061561T3 (pl) 2013-12-31
JP2021038252A (ja) 2021-03-11
AU2007287098B2 (en) 2013-08-15
KR20180003636A (ko) 2018-01-09
JP2015110577A (ja) 2015-06-18
AU2021201649A1 (en) 2021-04-08
EP2478907A2 (en) 2012-07-25
KR20150108946A (ko) 2015-09-30
EP2478907B1 (en) 2021-04-14
AU2015221447B9 (en) 2017-07-20
JP2024164147A (ja) 2024-11-26
JP2020114851A (ja) 2020-07-30
CN104306977A (zh) 2015-01-28
JP2022185091A (ja) 2022-12-13
SI2478907T1 (sl) 2021-08-31
IL197211A0 (en) 2009-12-24
ES2869343T3 (es) 2021-10-25
DK2478907T3 (da) 2021-05-25
AU2015221447B2 (en) 2016-12-15
JP6053279B2 (ja) 2016-12-27
AU2018271331A1 (en) 2018-12-20
JP2010501575A (ja) 2010-01-21
KR20200125776A (ko) 2020-11-04
IL227746A0 (en) 2013-09-30
HRP20210670T1 (hr) 2021-06-11
CA2661422A1 (en) 2008-02-28
PT2478907T (pt) 2021-05-26
EP2061561B1 (en) 2013-07-10
AU2007287098A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
CY1124221T1 (el) Συνθεσεις για τη θεραπεια του καρκινου
CY1110199T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
CY1123035T1 (el) Μεθοδοι και συνθεσεις με βαση συζευγματα τοξινης της διφθεριτιδας-ιντερλευκινης-3
CY1125077T1 (el) Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
EP2425874A3 (en) Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
CY1116779T1 (el) Αμιδο ενωσεις και η χρηση τους ως φαρμακευτικες ουσιες
CY1111263T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
NZ609420A (en) Fulvestrant compositions and methods of use
EP2056818A4 (en) COMPOSITIONS AND METHODS FOR NEUROPROTECTION
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
CY1117454T1 (el) Μεθοδοι και μεσα για την αποτελεσματικη παραλειψη του εξονιου 45 εις το προ-mrna της μυϊκης δυστροφιας τυπου duchenne
MXPA06000326A (es) Novedosos compuestos y composiciones que contienen esteroles y/o estanoles e inhibidores de biosintesis de colesterol, y su uso en el tratamiento o prevencion de una variedad de enfermedades y condiciones.
CY1106915T1 (el) Συνδυασμοι διαχωριστη(ων) χολικου οξεος και αναστολεα(ων) απορροφησης στερολης και θεραπειες για αγγειακες ενδειξεις
ATE518430T1 (de) Rohfaserformulierung und verfahren zu ihrer verabreichung
PE20230091A1 (es) Conjugados terapeuticos
NO2016012I1 (no) Betulin (bjørkeneverekstrakt)
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
CY1107816T1 (el) Η χρηση ενος συνδυασμου ενος αναστολεα αρωματασης, μιας προγεστερονης και ενος οιστρογονου για τη θεραπεια της ενδομητριωσης
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
CY1105607T1 (el) Η χρηση ενος η1 ανταγωνιστη και ριμεξαολης ως ενα ασφαλες στεροειδες για την θεραπεια ρινιτιδας
CY1110173T1 (el) Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης
TR200101766T2 (tr) Dehidroepiandrosteronun klatratları ve bunlara tekabül eden kompozisyonlar
BR112021025795A2 (pt) Terapia de combinação com bloqueio da semaforina-4d (sema4d) e terapia com dc1
CY1113417T1 (el) Παραγωγο πιπεριδινης